PL BioScience GmbH, a German manufacturer of Human Platelet Lysate used in cell therapy and regenerative medicine, has signed an exclusive distribution agreement with Summit Pharmaceuticals International Corp. for the Japanese market.

Under the arrangement, Summit Pharmaceuticals will distribute PL BioScience’s ELAREM Ultimate-FD PLUS, a GMP‑grade platelet lysate product, along with the company’s broader ELAREM portfolio for clinical applications. The companies said the partnership is intended to streamline procurement for Japanese customers and accelerate the adoption of qualified raw materials in early-stage development.

“We are excited to team up with SPI as this distribution agreement lays the groundwork for PL BioScience’s expansion into the Japanese market,” said Jungsoo Park, VP of Marketing and Sales, PL BioScience. “We believe there is a strong alignment between the two companies and shared values of high-quality products and customer support.”